Cannabis play RotoGro wraps up $4.5M raising

|

Published 05-OCT-2018 12:05 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Roto-Gro International Limited (ASX:RGI) is pleased to announce it has completed the final tranche of the $4.56 million capital raising to institutional and sophisticated investors announced on 20 June 2018.

The high demand capital raise, jointly managed by Barclay Wells Limited Pty Ltd and Emerald Capital Australia Pty Ltd, will allow RGI to fast-track the pursuit of strategic acquisitions in lawful cannabis licenses, nutrients and perishable foods by way of equity ownership or partnership.

The company is presently focussed on expanding the research and development facility in Caledon, Ontario, Canada, as well as bolstering its sales and management teams.

The final tranche of 5,418,698 shares completes a total of 12,000,000 new fully paid ordinary shares issued at $0.38 per share.

The company will also seek shareholder approval for the issue of 8,800,000 new unlisted options, exercisable at $0.65 and expiring two years from date of issue.

RGI updates on recent promising developments

Miracle Valley

Production continues for the Miracle Valley Medicinal Alternatives M.V.M.A. Ltd’s $2.3 million purchase order for the manufacture of RotoGro Rotational Hydroponic Gardens for their 29,000 square feet ‘state of the art’ cultivation and manufacturing facility in British Columbia, Canada.

RGI are now required to wait until end of October to access the site, in order to undertake RotoGro Installation. Meanwhile, the company has been working with Miracle Valley to finalise the design of a fertigation system for their expanded facility.

Gibio

The small cap is currently designing Gibio’s first flagship facility to incorporated automated unloading, washing, harvesting and packing of their Perishable crops. The 8’ Prototype Rotational Gardens are nearly complete with weekly collaboration between RotoGro and Gibio to continually refine the feeding and harvesting aspects of the Units.

Freshero

Freshero has a dedicated Grow Room at RGI’s Ontario facility. In mid-September, key members of Freshero’s management visited RGI’s Ontario and Nevada facilities, however the company has shortened and delayed the start of their trials, which are now set to commence mid-October.

It’s worth noting here that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.

RGI considers complementary acquisitions

As previously flagged by the company, it continues a focus on expanding into industry synergistic opportunities, including exploring strategic partnerships and complimentary acquisitions in related markets.

These markets include lawful cannabis license ownership, growing management services, industry leading nutrients, emerging tissue culture expertise and other supporting faculties of hydroponic growing.

RGI is now assessing opportunities to acquire a Cannabis Cultivation License in Canada and is consequently in discussions with a number of license holders. At this stage, all discussions are preliminary.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X